{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-106282","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.602308+00:00","generated_at":"2026-05-17T00:31:11.217335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rigel Q3 net income $27.9M, raises 2025 revenue guidance to $285-290M","bullets":["Q3 net income $27.9M ($1.46 diluted EPS) vs $12.4M ($0.70) in Q3 2024.","Total revenue $69.5M, record net product sales $64.1M (+65% YoY).","Raises 2025 total revenue guidance to ~$285-290M (prior $270-280M); product sales $225-230M.","TAVALISSE sales $44.7M (+70%), GAVRETO $11.1M (+56%), REZLIDHIA $8.3M (+50%).","R289 Ph1b dose expansion underway; Lilly terminates CNS collaboration (60-day effect)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-106282","json":"https://secwatch.observer/filing/0001104659-25-106282.json","markdown":"https://secwatch.observer/filing/0001104659-25-106282.md","text":"https://secwatch.observer/filing/0001104659-25-106282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/0001104659-25-106282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925106282/tm2530133d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:31:11.217335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}